Nestlé, a company engaged in advancing the role for nutritional therapy, completed the acquisition of Zenpep, a treatment, which is available in the United States, for exocrine pancreatic insufficiency, from Allergan, a global pharmaceutical company. Financial terms were not disclosed. "Our business has long history of working directly with healthcare professionals, offering them medical nutrition solutions for their patients in healthcare institutions and homecare settings. The additions of ZENPEP and VIOKACE now add a new and exciting dimension to that work.  We have been preparing for the business throughout the transition, since the deal was announced in January, and are ready to start working with our customers immediately," Anna Mohl, Nestlé Health Science US Business Executive Officer.